TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03938402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure
Description: Different levels of positive end-expiratory pressure (i.e., 5, 10 and 15 cm H2O) will be applied to the groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure
Description: Different levels of positive end-expiratory pressure (i.e., 5, 10 and 15 cm H2O) will be applied to the groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure
Description: Different levels of positive end-expiratory pressure (i.e., 5, 10 and 15 cm H2O) will be applied to the groups.
Study: NCT04550065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital game
Description: A digital family game with theme-based mini games (epidemic prevention, exercise, diet, communication and parenting)
Study: NCT05573620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included 'The dreamed professional exercise' -variation on 'imagine your funeral exercise'-, Ship's captain metaphor, Imaginal exposure, Physicalizing exercise, and Watching thoughts as graffiti.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included 'The dreamed professional exercise' -variation on 'imagine your funeral exercise'-, Ship's captain metaphor, Imaginal exposure, Physicalizing exercise, and Watching thoughts as graffiti.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In vivo exposure:
Description: The audience was made up of university students. Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain...). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality was delivered through Psious platform distributed in Spain by TEA and through a Virtual Reality equipment that included a Samsung S7 mobile and Samsung Gear VR glasses.~Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain...). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)
Study: NCT00453362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)
Description: FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine (FLT)
Description: FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib HCl
Description: Tablets taken orally 150 mg/day.
Study: NCT02382133

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal alar oxygen sensor
Description: Application of a nasal alar oxygen sensor
Study: NCT01671345

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Video
Description: A video intervention delivered prior to patients' visits with primary care physicians designed to increase use of active participatory communication (patient participation) behaviors, improved communication ratings, and improved medication adherence

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Attention control
Study: NCT00503256

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires each taking 60 minutes to complete.
Study: NCT03636906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV (GSK3389245A) lower dose formulation vaccine
Description: 1 dose of RSV (GSK3389245A) lower dose formulation vaccine administered intramuscularly at Day 1.
Study: NCT02381210

Intervention type: DEVICE
Intervention: Congo Red Dot Test
Description: The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.

Intervention type: DEVICE
Intervention: Congo Red Dot Test
Description: The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
Study: NCT04150367

Intervention type: DRUG
Intervention: Ethambutol
Description: Participants will get the dosage according to the instruction for use.
Study: NCT04127045

Intervention type: PROCEDURE
Intervention: IMN-Group
Description: Most intertrochanteric fractures are managed with an intramedullary nail, which allows for impaction at the fracture site. The intramedullary nail is placed directly into the marrow canal of the bone through an opening made at the top of the greater trochanter. A lag screw is then placed through the nail and up into the neck and head of the hip. As with the compression hip screw, sliding of the lag screw and impaction of the fracture take place.

Intervention type: PROCEDURE
Intervention: HA-Group
Description: In the older patient, the chance that the head of the femur is damaged in this way is higher. It is generally felt that for these displaced fractures, patients will do better if some of the components of the hip are replaced. In some cases, this can mean a replacement of the ball, or head of the femur (hemiarthroplasty).
Study: NCT04500353

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face mask application for CPAP and/or PPV delivery
Description: Face mask application for CPAP and/or PPV delivery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face mask application for CPAP and/or PPV delivery
Description: Face mask application for CPAP and/or PPV delivery
Study: NCT03739749

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic superior capsular reconstruction
Description: The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic superior capsular reconstruction
Description: The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic superior capsular reconstruction
Description: The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic superior capsular reconstruction
Description: The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic superior capsular reconstruction
Description: The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic superior capsular reconstruction
Description: The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft
Study: NCT00715065

Intervention type: PROCEDURE
Intervention: fMRI Scan
Description: Subjects will undergo a functional MRI scan of the head lasting \~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.

Intervention type: PROCEDURE
Intervention: fMRI Scan
Description: Subjects will undergo a functional MRI scan of the head lasting \~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.
Study: NCT02006992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RTF Infant Formula
Description: a RTF extensively hydrolyzed infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powder Infant Formula
Description: a powdered extensively hydrolyzed infant formula.
Study: NCT01550900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: Starting dose: 500 mg by mouth daily for 1 week with weekly increases of 250 mg daily to target dose of 1000 mg daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets by mouth 1 time a day.
Study: NCT01361802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol Spray
Description: low dose Ambroxol Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol Spray
Description: medium dose Ambroxol Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol Spray
Description: high dose Ambroxol Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spray
Description: Placebo Spray
Study: NCT02701114

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Adductor Canal Block
Description: Continuous Nerve Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal Adductor Canal Block
Description: Continuous Nerve Block
Study: NCT03736382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild intermittent hypoxia
Description: Participants will be exposed to twelve two minute episodes of mild intermittent hypoxia 5 days a week for 3 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham protocol
Description: Participants will be exposed to twelve two minute episodes of sham mild intermittent hypoxia (i.e. room air) 5 days a week for 3 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: All participants will be treated with CPAP each night for a duration of 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: All participants will be treated with CPAP each night for a duration of 3 weeks.
Study: NCT02210390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho education
Description: Psycho-education Sessions will be offered weekly basis
Study: NCT02512393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
Study: NCT00587470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Maximum vasodilation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atacand
Description: maximum vasodilation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03497897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS006 20 mg
Description: LYS006 20 mg, capsules, oral administration, BID, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS006 2 mg
Description: LYS006 2 mg, capsules, oral administration, BID, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, capsules, oral administration, BID, for 12 weeks
Study: NCT01914952

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CaHMB capsule
Description: 1.0 gram of CaHMB powder in a gelatin capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB free acid gelcap
Description: 0.8 g HMB free acid is a soft gel capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB free acid mixed in water
Description: 0.8 g HMB free acid in water
Study: NCT00662571

Intervention type: DRUG
Intervention: acamprosate
Description: acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day
Study: NCT02743130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackcurrant Nectar
Description: Consumption of a single dose (300 ml)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lingonberry Nectar
Description: Consumption of a single dose (300 ml)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Consumption of a single dose (300 ml)
Study: NCT01725698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant
Study: NCT01049893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound AC220
Description: Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
Study: NCT04119739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization
Description: Manual therapy maneuver performed in the upper limb.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Arginine
Description: Oral tablets
Study: NCT04295148

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction with Semitendinosus graft
Description: Participants will undergo Anterior Cruciate Ligament Reconstruction with Semitendinosus graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction with Quadriceps tendon-bone graft
Description: Participants will undergo Anterior Cruciate Ligament Reconstruction with Quadriceps tendon-bone graft
Study: NCT04285281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin oral capsules
Description: Oral capsule pharmaceutical treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization
Description: Manual therapy maneuver performed in the upper limb.
Study: NCT04603209

Intervention type: RADIATION
Intervention: Intraoperative Radiation Therapy (IORT)
Description: IORT involving 50kV Xrays to a dose of 20 Gy during breast-conserving surgery
Study: NCT03261323

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Breast Reconstruction
Description: Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery. Reconstruction will be attempted immediately after mastectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Breast Reconstruction
Description: Risk reduction strategies on smoking, weight, and chronic disease control will be offered. The individual risk will be recalculated every three months. Delayed breast reconstruction will be offered when core cancer therapies (mastectomy, chemotherapy and radiation) are complete. Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery.
Study: NCT01914952

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CaHMB in water
Description: 1.0 g CaHMB powder mixed in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB free acid
Description: 0.8 g HMB free acid
Study: NCT03776656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Daily oral administration
Study: NCT03204149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MC-8XL low level laser device and Standard wound care
Description: The MC-8XL, a handheld Low Level Laser Therapy (LLLT) device, comprised of an infrared laser diode that generates wavelength of 808 nm and a green laser diode with a wavelength of 525 nm will be used to treat the experimental group.~Along with the active LLLT, generally accepted standard wound care procedures will be used during the clinical trial by a qualified study nurse or doctor. These procedures will include wound cleaning and drying before irradiation with the laser device (sham or active). Each ulcer will be also assessed and debrided if needed.~After irradiation, each ulcer will be dressed with saline gauze dressing and offloaded.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser device and Standard wound care
Description: The Sham device is of similar appearance, emitting only green light for indication with a wavelength of 525 nm of a low power, with inactive IR laser which will be used in the Control group.~Along with the sham device, the same generally accepted standard wound care procedures will be used.
Study: NCT03012373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ear acupressure alone
Description: The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes then were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ear acupressure alone
Description: The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes then were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus ear acupressure
Description: Acupuncture included Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation was conducted. The frequency of electrical stimulation was 5 Hz and wave form was adjustable. The intensities of the stimulation were increased in 1 mA increments to maximal tolerable intensity. At the same time, The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes. After 15 minutes treatment, acupuncture needles were removed and magnet pellets were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus ear acupressure
Description: Acupuncture included Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation was conducted. The frequency of electrical stimulation was 5 Hz and wave form was adjustable. The intensities of the stimulation were increased in 1 mA increments to maximal tolerable intensity. At the same time, The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes. After 15 minutes treatment, acupuncture needles were removed and magnet pellets were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
Study: NCT03294551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine Reminder Recall - Autodialer
Description: Investigators will send out HPV vaccine reminder recall notices via autodialer message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine Reminder Recall - Texting
Description: Investigators will send out HPV vaccine reminder recall notices via text message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
Study: NCT00576238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone valerate
Description: Topical application according to a fixed schedule for three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone valerate
Description: Topical application according to a fixed schedule for three weeks
Study: NCT01116778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eN-Lac®
Description: One capsule with 2x10\^9 colony forming unit (cfu) LP GMNL-32, once daily, po

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: One placebo capsule, once daily, po
Study: NCT00907179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH 589
Description: LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
Study: NCT03207373

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stress test (ECG)
Description: Every study participant undergoes a standard diagnostic stress ECG
Study: NCT00576238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea
Description: Topical application twice daily for up to 6 months
Study: NCT02269722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular compression device- RADAR TM-Short clamp time
Description: A clamp is placed on the radial artery following cardiac catheterization for 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular compression device RADAR TM-Long clamp time
Description: A clamp is placed on the radial artery following cardiac catheterization for 20 minutes